The Value of Single-cycle TPF Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Two Phase Ⅲ trials (TAX323 and TAX324) showed induction chemotherapy adding docetaxel to
cisplatin plus fluorouracil (TPF) could significant improve survival in head and neck cancer,
and a Phase Ⅱ trial from Hong Kong by Hui and colleges with this strategy has also been
reported in nasopharyngeal carcinoma (NPC). However, whether three cycles induction could
delay the whole time of treatment and reduce the survival benefit are still unknown. A
retrospective study of one cycle TPF induction chemotherapy by the investigators group (not
yet published) could improve survival in NPC. It encourage us to conduct this clinical trial.